Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
For-profit education company, DeVry Inc. ( DV - Analyst Report ) is all set to report its fourth quarter and fiscal 2012 results after the closing bell on August 9, 2012. The Zacks Consensus Estimate for the fourth quarter is pegged at 47 cents (estimated year-over-year decline of 56.5%) on revenues of $510 million (year-over-year increase of 6.8%).
For fiscal 2012, the Zacks Consensus Estimate is $3.21 (estimated year-over-year decline of 31.4%) on revenues of $2.1 billion (year-over-year increase of 3.8%).
Third Quarter Recap
DeVry’s third quarter 2012 earnings of $1.00 per share declined 24.2% from the year-ago period due to a decline in revenues and resultant margin contraction. Earnings were however in line with the Zacks Consensus Estimate.
DeVry’s quarterly net sales fell 3.9% to $540.8 million due to sluggish student enrollments in the quarter, especially at DeVry University and Carrington Colleges. Sales were slightly above the Zacks Sales Estimate of $532 million.
The company’s total post secondary enrollments were down 3.7% over the prior-year quarter. The decline in enrollment is the result of persistent unemployment, overall economic downturn and subsequent decline in student demand, heightened competition and modifications made to the business to comply with new regulations.
Read our full report at DeVry Meets EPS, Enrollments Weak.
Agreement of Estimate Revisions
Over the past 30 days, 13 of the 14 estimates on DeVry have been revised for both the fourth quarter and full year 2012. All the revisions have been in the downward direction. There have been no estimate revisions over the last 7 days.
In late July 2012, DeVry announced a disappointing financial outlook for the fourth quarter of 2012 and said that the company plans to cut 570 jobs. Both revenue and earnings are expected to decline from year ago as well as sequential levels, largely due to lower enrollments. The downward pressure on earnings estimates was in response to the guidance cut.
Magnitude of Estimate Revisions
Given the large number of estimate revisions, the consensus estimate for the fourth quarter of fiscal 2012 has gone down over the last 30 days from 79 cents to 47 cents. The consensus estimate for fiscal 2012 has also gone down from $3.53 to $3.21 over the last 30 days. There has been no change in estimates over the last 7 days.
Surprise History
Over the past four quarters, DeVry has surpassed estimates once, matched once and missed two times, thereby resulting in an average earnings estimate of negative 5.56%. The company recorded a maximum positive surprise of 4.85% in the fourth quarter of 2011.
Our Recommendation
The stock carries a Zacks #5 Rank (a short-term ‘Strong Sell’ rating) following the dim outlook provided for the upcoming quarter.
Read the full Analyst Report on DV